Cancer Research and Treatment

Volume 40(3); September 2008

Original Articles

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer: Jung Hwan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Suee Lee, Sung-Hyun Kim, Dae-Cheol Kim, Jin-Hwa Lee, Hyung-Sik Lee, Se-Heun Cho, Hyo-Jin Kim; Cancer Res Treat. 2008;40(3):101-105. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.101

Purpose

Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane.

Materials and Methods

We evaluated the use of a GP regimen (1,000 mg/m² gemcitabine administered on days 1 and 8 plus 60 mg/m² cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.

Results

The median patient age was 49 years (age range, 35~69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14~44%). The median time to progression was 5.2 months (95% CI, 3.6~6.8 months). Median survival was 19.5 months (95% CI, 11.2~27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths.

Conclusions

Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.

Citations

Citations to this article as recorded by

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
The Korean Journal of Internal Medicine.2021; 36(1): 182. CrossRef
Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Jinfeng Zhang, Mingxi Lin, Yizi Jin, Linhan Gu, Ting Li, Baoying Yuan, Biyun Wang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Jian Zhang, Xichun Hu
Breast Cancer Research and Treatment.2020; 182(3): 719. CrossRef
Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
Jung Sun Kim, In Hae Park, Keun Seok Lee, Jungsil Ro
Journal of Breast Cancer.2014; 17(4): 339. CrossRef
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
Pramod K. Julka, Raju T. Chacko, Shona Nag, Rajinder Parshad, Aravindan Nair, Chaitanyanand B. Koppiker, Fen Chao Richard Xue, Helen Barraclough, Navreet Dhindsa, Anil Seth, Anurita Majumdar, Tarun Puri
Breast Cancer.2013; 20(4): 357. CrossRef
Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer
Tao Wang, Shaohua Zhang, Min Zeng, Xinyou Lu, Ge Shen, Shikai Wu, Santai Song, Zefei Jiang
Medical Oncology.2012; 29(1): 56. CrossRef
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H J Stemmler, D diGioia, W Freier, H W Tessen, G Gitsch, W Jonat, W Brugger, E Kettner, W Abenhardt, H Tesch, H J Hurtz, S Rösel, O Brudler, V Heinemann
British Journal of Cancer.2011; 104(7): 1071. CrossRef
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Ali I. Shamseddine, Fadi S. Farhat
Chemotherapy.2011; 57(6): 468. CrossRef
Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
Binghe Xu, Zefei Jiang, Sung-Bae Kim, Shiying Yu, Jifeng Feng, Artur Malzyner, Auro del Giglio, Hyun C. Chung, Li Jun Shen, Daniel Lee Kay Pen
Breast Cancer.2011; 18(3): 203. CrossRef

10,603 View
67 Download
8 Crossref

A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer: Gun Hi Kang, Gwang Sil Kim, Hyo Rak Lee, Young Jin Yuh, Sung Rok Kim; Cancer Res Treat. 2008;40(3):106-110. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.106

Abstract PDF PubReader ePub

Purpose

We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer.

Materials and Methods

Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m² on day 1, 5-FU 1 g/m²/day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m² on day 1 were administered. This regimen was repeated every 3 weeks.

Results

A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0~77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed.

Conclusions

The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.

Citations

Citations to this article as recorded by

Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis
Jia Luo, ZhouXue Wu, Yun Lu, Kang Xiong, Qian Wen, Ling Zhao, BiQiong Wang, Yan Gui, ShaoZhi Fu
International Journal of Biological Macromolecules.2020; 152: 718. CrossRef
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells
Gaetano Marverti, Gaia Gozzi, Eleonora Maretti, Angela Lauriola, Leda Severi, Francesca Sacchetti, Lorena Losi, Salvatore Pacifico, Stefania Ferrari, Glauco Ponterini, Eliana Leo, Maria Paola Costi, Domenico D’Arca
International Journal of Molecular Sciences.2020; 21(12): 4452. CrossRef
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
Cui Chen, Feng-hua Wang, Xin An, Hui-yan Luo, Zhi-qiang Wang, Ying Liang, Le Zhang, Yu-hong Li
Cancer Chemotherapy and Pharmacology.2013; 71(2): 371. CrossRef
Targeted therapy for gastric cancer—current status
Jan Kulig, Piotr Kołodziejczyk, Piotr Kulig, Janusz Legutko
Journal of Oncology Pharmacy Practice.2013; 19(1): 75. CrossRef
Targeted Therapies for Gastric Cancer
Jaclyn Yoong, Michael Michael, Trevor Leong
Drugs.2011; 71(11): 1367. CrossRef
Down-Regulation of Human Epidermal Growth Factor Receptor 2/neu Oncogene by Corosolic Acid Induces Cell Cycle Arrest and Apoptosis in NCI-N87 Human Gastric Cancer Cells
Myung Sun Lee, Eun Young Cha, Phuong Thien Thuong, Ji Yeon Kim, Moon Sang Ahn, Ji Young Sul
Biological and Pharmaceutical Bulletin.2010; 33(6): 931. CrossRef
Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
Hye Ryun Kim, Seong Ha Cheon, Kwang-Hun Lee, Jung Ryun Ahn, Hei-Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
International Journal of Hyperthermia.2010; 26(4): 305. CrossRef

9,543 View
63 Download
7 Crossref

Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea: Jeong A Park, Eun Kyung Kim, Hyoung Jin Kang, Hee Young Shin, Il Han Kim, Hyo Seop Ahn; Cancer Res Treat. 2008;40(3):111-115. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.111

Abstract PDF PubReader ePub

Purpose

Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients.

Materials and Methods

We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005.

Results

The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors.

Conclusions

The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.

Citations

Citations to this article as recorded by

Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India
Soumyajit Roy, Sushmita Pathy, Bidhu K. Mohanti, Subhash Chander, Ahitagni Biswas
Journal of Pediatric Hematology/Oncology.2017; 39(2): e62. CrossRef
Pediatric rhabdomyosarcoma in India: A single-center experience
Deepak Bansal, Anirban Das, Amita Trehan, Rakesh Kapoor, Naresh K. Panda, Radhika Srinivasan, Nandita Kakkar, Kushaljit S. Sodhi, Akshay K. Saxena, Katragadda Lakshmi Narasimha Rao
Indian Pediatrics.2017; 54(9): 735. CrossRef
The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma
Yunseon Choi, Do Hoon Lim
Radiation Oncology Journal.2016; 34(4): 290. CrossRef
Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon
Maysaa Salman, Hani Tamim, Fouad Medlej, Tarek El-Ariss, Fatima Saad, Fouad Boulos, Toufic Eid, Samar Muwakkit, Nabil Khoury, Miguel Abboud, Raya Saab
Pediatric Hematology and Oncology.2012; 29(4): 322. CrossRef
Solid tumours of childhood
Bruce O. Okoye
Surgery (Oxford).2010; 28(8): 382. CrossRef
Primary meningeal rhabdomyosarcoma associated with chronic subdural effusion
Ji Yeoun Lee, Bo Sung Kim, Ji Hoon Phi, Hyoung Jin Kang, Sung-Hye Park, Kyu-Chang Wang, Il Han Kim, Byung-Kyu Cho, Seung-Ki Kim
Journal of Neurosurgery: Pediatrics.2010; 5(2): 167. CrossRef

10,120 View
38 Download
6 Crossref

Gemcitabine and Carboplatin Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Feasibility Study: Young Jin Yuh, Hyo Rak Lee, Sung Rok Kim; Cancer Res Treat. 2008;40(3):116-120. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.116

Abstract PDF PubReader ePub

Purpose

Although platinum based chemotherapy is known to improve the survival duration for the patients with non-small cell lung cancer, the role of platinum for elderly patient is not yet clear. We administered gemcitabine and carboplatin combination therapy to elderly patients with NSCLC. The aim of this study was to evaluate the efficacy and toxicities of this regimen for elderly patients.

Materials and Methods

The eligibility criteria were as follows: pathologically confirmed NSCLC, an age ≥65 years, advanced disease with stage IIIB or IV and the patients were chemotherapy-naive. The treatment regimen was as follows; gemcitabine 1,000 mg/m² was administered on days 1 and 8 and carboplatin AUC=5 was administered on day 1. This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of the response rate, the time to progression and the overall survival duration.

Results

From Dec 2001 to Feb 2005, a total of 20 patients were entered into this study. The median patient age was 68 years (range: 65~75). 19 patients were evaluable for their treatment response. A partial response was obtained in 8 patients (response rate: 42.1%, 95% CI: 19.4~64.8%). The median time to progression and the survival duration were 136 days and 453 days, respectively. Among a total of 65 cycles of treatment, grade 3 or 4 leukopenia and thrombocytopenia were observed in 7.7% and 13.9% of the cycles, respectively. Grade 3 or 4 vomiting was observed in 7.7% of the cycles. Grade 3 skin rash developed in 1.5% of the cycles. 1 patient died of septic shock after chemotherapy.

Conclusions

Gemcitabine and carboplatin combination chemotherapy was relatively safe and effective for treating elderly patients with NSCLC.

Citations

Citations to this article as recorded by

Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Case-Control Study
Nan-Jie Zhao, Zhao Sun, Yuzhou Wang, Xiaohong Ning, Ning Jia, Changting Meng, Yingyi Wang
Translational Oncology.2014; 7(4): 508. CrossRef
Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?
Seung Tae Kim, Hae-Yun Jung, Jae Sook Sung, Uk Hyun Jo, Tomoaki Tanaka, Koichi Hagiwara, Kyong Hwa Park, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim
American Journal of Clinical Oncology.2013; 36(1): 57. CrossRef
Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
Seung Tae Kim, Jae Sook Sung, Uk Hyun Jo, Kyong Hwa Park, Sang Won Shin, Yeul Hong Kim
Medical Oncology.2013;[Epub] CrossRef
Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer
Kyu-Hyoung Lim, Hui-Young Lee, Seo-Young Song
Chinese Medical Journal.2013; 126(24): 4644. CrossRef
Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)
Fumio Imamura, Makoto Nishio, Rintaro Noro, Masahiro Tsuboi, Norihiko Ikeda, Akira Inoue, Yoshinobu Ohsaki, Yukio Kimura, Kazumi Nishino, Junji Uchida, Takeshi Horai
Chemotherapy.2011; 57(4): 357. CrossRef
Carboplatin and Gemcitabine in First-Line Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Data from a Retrospective Study
G. Genestreti, N. Giovannini, M. Frizziero, M. Maglie, S. Sanna, S. Cingarlini, A.M. Molino, S. Piciucchi, G.L. Cetto, A. Santo
Journal of Chemotherapy.2011; 23(4): 232. CrossRef
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
Seung Tae Kim, Jeeyun Lee, Jeong‐hoon Kim, Young‐Woong Won, Jong‐Mu Sun, Jina Yun, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn
Cancer.2010; 116(12): 3025. CrossRef
Treatment of Older Patients With Non–Small-Cell Lung Cancer: Walking the Therapeutic Tightrope
George R. Simon
Journal of Clinical Oncology.2010; 28(4): 523. CrossRef

9,178 View
67 Download
8 Crossref

Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity: Ho Sup Lee, Chang Bae Son, Seong Hoon Shin, Yang Soo Kim; Cancer Res Treat. 2008;40(3):121-126. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.121

Abstract PDF PubReader ePub

Purpose

Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.

Materials and Methods

Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.

Results

Of the 86 participants (mean age, 48.5 years; range 20~65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.

Conclusions

The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.

Citations

Citations to this article as recorded by

Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study
Ling-Ming Tseng, Fang Ming Chen, Shou-Tung Chen, Fiona Tsui-Fen Cheng, Tsu-Yi Chao, Ming-Shen Dai, Woei-Yau Kao, Ming-Hsin Yeh, Dar-Ren Chen, Liang-Chih Liu, Hewi Chung Wang, Hong-Tai Chang, Being Whey Wang, Jyh-Cherng Yu, Shin Cheh Chen, Guo-Shiou Liao,
Oncology Research and Treatment.2024; 47(10): 484. CrossRef
Low-Dose Radiation Reduces Doxorubicin-Induced Myocardial Injury Through Mitochondrial Pathways
Di Zhao, Xin Jiang, Xinxin Meng, Dandan Liu, Yanwei Du, Lijing Zhao, Hongyu Jiang
Dose-Response.2023;[Epub] CrossRef
Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka
Jayasinghe Arachchige Nirosha Sandamali, Ruwani Punyakanthi Hewawasam, Madappuli Arachchige Chaminda Sri S Fernando, Kamani Ayoma Perera Wijewardana Jayatilaka
BMC Cancer.2023;[Epub] CrossRef
Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope
Rishabh Mittal, Sarath Krishnan M P, Rahul Saxena, Ananyan Sampath, Bela Goyal
Cancer Treatment and Research Communications.2023; 36: 100750. CrossRef
Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
Xinxin Zhang, Yuxi Sun, Yanli Zhang, Fengqi Fang, Jiwei Liu, Yunlong Xia, Ying Liu
Journal of Cardiovascular Development and Disease.2022; 9(11): 372. CrossRef
Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial
Farina Hellmann, Swantje Völler, Miriam Krischke, David Jamieson, Nicolas André, Gianni Bisogno, Alan Boddy, Georg Hempel
European Journal of Drug Metabolism and Pharmacokinetics.2020; 45(3): 413. CrossRef
Cardiotoxicity of Anthracyclines
Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla
Frontiers in Cardiovascular Medicine.2020;[Epub] CrossRef
The Role of Biomarkers in Cardio-Oncology
Kajaluxy Ananthan, Alexander R. Lyon
Journal of Cardiovascular Translational Research.2020; 13(3): 431. CrossRef
Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
Letitia Elena Radu, Roxana Corina Sfetea, Constantin Virgiliu Arion, Anca Colita
Revista Romana de Medicina de Laborator.2020; 28(2): 133. CrossRef
Oncologic therapies associated with cardiac toxicities: how to minimize the risks
Daniela Cardinale, Federica Stivala, Carlo M. Cipolla
Expert Review of Anticancer Therapy.2019; 19(5): 359. CrossRef
Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
Rohit Moudgil, Parag A. Parekh
Heart Failure Reviews.2018; 23(2): 255. CrossRef
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
Faisal Imam, Naif O. Al-Harbi, Mohammed M. Al-Harbia, Hesham M. Korashy, Mushtaq Ahmad Ansari, Mohamed M. Sayed-Ahmed, Mahmoud N. Nagi, Muzaffar Iqbal, Md. Khalid Anwer, Imran Kazmi, Muhammad Afzal, Saleh Bahashwan
Cardiovascular Toxicology.2017; 17(1): 58. CrossRef
Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy
Daniela Cardinale, Gina Biasillo, Michela Salvatici, Maria Teresa Sandri, Carlo Maria Cipolla
Expert Review of Molecular Diagnostics.2017; 17(3): 245. CrossRef
Alternative Biomarkers for Combined Biology
Yong-Hyun Kim, Jennifer Kirsop, Wai Hong Wilson Tang
Heart Failure Clinics.2017; 13(2): 381. CrossRef
Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts
Gina Biasillo, Carlo M. Cipolla, Daniela Cardinale
Current Oncology Reports.2017;[Epub] CrossRef
Cardiovascular Complications of Cancer Therapy
Hui-Ming Chang, Rohit Moudgil, Tiziano Scarabelli, Tochukwu M. Okwuosa, Edward T.H. Yeh
Journal of the American College of Cardiology.2017; 70(20): 2536. CrossRef
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Giuseppe Curigliano, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, Carlo Maria Cipolla
CA: A Cancer Journal for Clinicians.2016; 66(4): 309. CrossRef
Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
Hesham M. Korashy, Ibraheem M. Attafi, Mushtaq A. Ansari, Mohammed A. Assiri, Osamah M. Belali, Sheik F. Ahmad, Ibrahim A. AL-Alallah, Fawaz E.Al Anazi, Abdulqader A. Alhaider
Toxicology Letters.2016; 252: 50. CrossRef
Role of biomarkers in monitoring antiblastic cardiotoxicity
Giuseppina Novo, Christian Cadeddu, Vincenzo Sucato, Pasquale Pagliaro, Silvio Romano, Carlo G. Tocchetti, Concetta Zito, Luca Longobardo, Savina Nodari, Maria Penco
Journal of Cardiovascular Medicine.2016; 17: e27. CrossRef
Biomarkers and Cancer Therapy-Related Cardiac Dysfunction
Prateek Sharma, Mahin Rehman, Javed Butler, Michelle W. Bloom
Current Cardiovascular Risk Reports.2016;[Epub] CrossRef
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy
Christine Henri, Therese Heinonen, Jean-Claude Tardif
Biomarkers in Cancer.2016; 8s2: BIC.S31798. CrossRef
Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity
YA-DI WANG, SU-XIAN CHEN, LI-QUN REN
Oncology Letters.2016; 11(5): 3483. CrossRef
Mitogen-Activated Protein Kinases Pathways Mediate the Sunitinib-Induced Hypertrophy in Rat Cardiomyocyte H9c2 Cells
Hesham Mohamed Korashy, Hani A. Al-Suwayeh, Zaid H. Maayah, Mushtaq Ahmad Ansari, Sheikh Fayaz Ahmad, Saleh A. Bakheet
Cardiovascular Toxicology.2015; 15(1): 41. CrossRef
Cardiotoxicity due to Chemotherapy: the Role of Biomarkers
Patrick L. Stevens, Daniel J. Lenihan
Current Cardiology Reports.2015;[Epub] CrossRef
Cardiac Complications of Chemotherapy: Role of Biomarkers
Alessandro Colombo, Maria T. Sandri, Michela Salvatici, Carlo M. Cipolla, Daniela Cardinale
Current Treatment Options in Cardiovascular Medicine.2014;[Epub] CrossRef
Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity
Eric S. Christenson, Theodore James, Vineet Agrawal, Ben H. Park
Clinical Biochemistry.2014;[Epub] CrossRef
BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography
Dorthe Skovgaard, Philip Hasbak, Andreas Kjaer, Claudio Moretti
PLoS ONE.2014; 9(5): e96736. CrossRef
Using Cardiac Biomarkers and Treating Cardiotoxicity in Cancer
Alessandro Colombo, Daniela Cardinale
Future Cardiology.2013; 9(1): 105. CrossRef
Exaggerated NT‐proBNP Production in Patients With Hematologic Malignancies: A Case Series
Aileen Andreu, Maya Guglin
Congestive Heart Failure.2012; 18(6): 333. CrossRef
Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience
Erkan Dogan, Hikmet Yorgun, Ibrahim Petekkaya, Necla Ozer, Kadri Altundag, Yavuz Ozisik
Medical Oncology.2012; 29(5): 3232. CrossRef
NT-ProBNP and cardiac troponin I in virulent canine babesiosis
Remo Lobetti, Robert Kirberger, Ninette Keller, Frank Kettner, Eran Dvir
Veterinary Parasitology.2012; 190(3-4): 333. CrossRef
Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo
Lidia Boccardi, Daniela Cardinale, Maurizio Civelli, Chiara Lestuzzi, Carlo Materazzo, Nicola Maurea, Ines Monte, Stefano Oliva, Patrizia Piotti, Giuseppina Quattrocchi, Elisabetta Rossi, Giuseppe Toglia
Journal of Cardiovascular Echography.2011; 21(1): 32. CrossRef
Role of biomarkers in cardioncology
Daniela Cardinale, Michela Salvatici, Maria T. Sandri
Clinical Chemistry and Laboratory Medicine (CCLM).2011;[Epub] CrossRef
Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice
Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh
Journal of Controlled Release.2010; 142(1): 101. CrossRef
Cardiac Involvement in Patients with Hematologic Malignancies
Alessandro Allegra, Andrea Alonci, Sabina Russo, Antonino Cannavò, Giuseppa Penna, Arianna D'Angelo, Giacomo Bellomo, Caterina Musolino
Journal of Investigative Medicine.2010; 58(7): 859. CrossRef

10,494 View
80 Download
35 Crossref

The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer: Yong Park, Jee Won Kim, Dae Sik Kim, Eui Bae Kim, Se Jong Park, Jin Yong Park, Woo Suk Choi, Jong Gyu Song, Hee Yun Seo, Sang Cheul Oh, Byung Soo Kim, Jong Jae Park, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2008;40(3):127-132. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.127

Abstract PDF PubReader ePub

Purpose

Bone Morphogenetic Proteins (BMPs) are members of the TGF-β superfamily and it has been demonstrated that BMPs enhance migration, invasion and metastasis. The purpose of this study was to identify the association between the serum BMP-2 level and the progression status of gastric cancer.

Materials and Methods

Fifty-five patients with metastatic gastric cancer (metastatic disease group), six patients with early gastric cancer without lymph node metastasis (the EGC group), and ten healthy control subjects were enrolled in this study. The serum BMP-2 level was quantified by use of a commercially available ELISA kit. In EGC group patients and patients with metastatic disease, whole blood was obtained before endoscopic mucosal resection and before the commencement of a scheduled cycle of systemic chemotherapy, respectively.

Results

No significant difference in the mean serum BMP-2 levels was observed between the control subjects and the EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p=1.0). However, the metastatic disease group patients had a significantly higher level of serum BMP (179.61 pg/ml) than the control subjects and EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p<0.0001). Moreover, the mean serum BMP-2 level from patients with a bone metastasis was significantly higher than the mean serum BMP-2 level from patients without a bone metastasis (204.73 pg/ml versus 173.33 pg/ml, p=0.021).

Conclusions

BMP-2 seems to have a role in progression to metastatic disease in gastric cancer, especially in the late stage of tumorigenesis, including invasion and metastasis. BMP-2 may facilitate bone metastasis in gastric cancer. To confirm these findings, further studies are required with tissue specimens and the use of a cancer cell line.

Citations

Citations to this article as recorded by

Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis—A Pilot Prospective Observational Cohort Study
Lazar Chisavu, Viviana Mihaela Ivan, Adelina Mihaescu, Flavia Chisavu, Oana Schiller, Luciana Marc, Flaviu Bob, Adalbert Schiller
Diagnostics.2024; 14(6): 664. CrossRef
Duality of bone morphogenetic proteins in cancer: A comprehensive analysis
Tanu Sharma, Anmol Kapoor, Chandi C. Mandal
Journal of Cellular Physiology.2022; 237(8): 3127. CrossRef
BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer
Zilu Chen, Liyue Yuan, Xiaopeng Li, Junhui Yu, Zhengshui Xu
Cell Cycle.2022; 21(21): 2298. CrossRef
Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour
Alejandro Álvarez-Artime, Belén García-Soler, Rosa María Sainz, Juan Carlos Mayo
International Journal of Molecular Sciences.2021; 22(11): 5560. CrossRef
Magnesium ions regulate mesenchymal stem cells population and osteogenic differentiation: A fuzzy agent-based modeling approach
Jalil Nourisa, Berit Zeller-Plumhoff, Heike Helmholz, Bérengère Luthringer-Feyerabend, Vladimir Ivannikov, Regine Willumeit-Römer
Computational and Structural Biotechnology Journal.2021; 19: 4110. CrossRef
BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract
Yongchun Zhang, Jianwen Que
Annual Review of Physiology.2020; 82(1): 251. CrossRef
Relaxin enhances bone regeneration with BMP‐2‐loaded hydroxyapatite microspheres
Sahitya Injamuri, Mohamed N. Rahaman, Youqu Shen, Yue‐Wern Huang
Journal of Biomedical Materials Research Part A.2020; 108(5): 1231. CrossRef
Annatto-Derived Tocotrienol Promotes Mineralization of MC3T3-E1 Cells by Enhancing BMP-2 Protein Expression via Inhibiting RhoA Activation and HMG-CoA Reductase Gene Expression

Wan Nuraini Wan Hasan, Kok-Yong Chin, Norzana Abd Ghafar, Ima Nirwana Soelaiman
Drug Design, Development and Therapy.2020; Volume 14: 969. CrossRef
Detection of circulating BMP5 as a risk factor for Barrett’s esophagus
Ana C. P. Correia, Silvia Calpe, Nahid Mostafavi, Sanne Johanna Maria Hoefnagel, Maria del Carmen Sancho-Serra, Patricia S. de Koning, Kausilia K. Krishnadath
Scientific Reports.2020;[Epub] CrossRef
The Dual Role of Bone Morphogenetic Proteins in Cancer
Duc-Hiep Bach, Hyen Joo Park, Sang Kook Lee
Molecular Therapy - Oncolytics.2018; 8: 1. CrossRef
Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
Tobias Sinnberg, Heike Niessner, Mitch P. Levesque, Christoph Dettweiler, Claus Garbe, Christian Busch
Biology Open.2018;[Epub] CrossRef
Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis
Bum Sik Tae, Seok Cho, Hyun Cheol Kim, Cheol Hwan Kim, Seok Ho Kang, Jeong Gu Lee, Je Jong Kim, Hong Seok Park, Jun Cheon, Mi Mi Oh, Sung Gu Kang
Scientific Reports.2018;[Epub] CrossRef
Computational model of mesenchymal migration in 3D under chemotaxis
F. O. Ribeiro, M. J. Gómez-Benito, J. Folgado, P. R. Fernandes, J. M. García-Aznar
Computer Methods in Biomechanics and Biomedical Engineering.2017; 20(1): 59. CrossRef
Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy
Haijun Tian, Jie Zhao, Elsa J. Brochmann, Jeffrey C. Wang, Samuel S. Murray
Cytokine & Growth Factor Reviews.2017; 34: 73. CrossRef
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells
Min Hu, Facai Cui, Fengzhen Liu, Jinlin Wang, Xiaoxia Wei, Yi Li
International Journal of Oncology.2017; 50(1): 193. CrossRef
Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis
Jian Sun, Xuan Liu, Hong Gao, Long Zhang, Qing Ji, Ziyuan Wang, Lihong Zhou, Yan Wang, Hua Sui, Zhongze Fan, Qi Li
Oncotarget.2017; 8(7): 11489. CrossRef
BMP10 inhibited the growth and migration of gastric cancer cells
Haiming Lei, Jian Wang, Peihua Lu, Xinghua Si, Koulan Han, Tingyan Ruan, Junjie Lu
Tumor Biology.2016; 37(3): 3025. CrossRef
How does the pathophysiological context influence delivery of bone growth factors?
Xiaohua Yu, Darilis Suárez-González, Andrew S. Khalil, William L. Murphy
Advanced Drug Delivery Reviews.2015; 84: 68. CrossRef
Inactivation of the Phosphatidylinositol 3‐Kinase/Akt Pathway is Involved in BMP9‐mediated Tumor‐suppressive Effects in Gastric Cancer Cells
Liang Duan, Liwei Ye, Rui Wu, Haiyan Wang, Xueru Li, Huan Li, Shimei Yuan, He Zha, Hui Sun, Yunyuan Zhang, Xian Chen, Yan Zhang, Lan Zhou
Journal of Cellular Biochemistry.2015; 116(6): 1080. CrossRef
Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2
Yun-Jung Choi, Patrick N. Ingram, Kun Yang, Lan Coffman, Mangala Iyengar, Shoumei Bai, Dafydd G. Thomas, Euisik Yoon, Ronald J. Buckanovich
Proceedings of the National Academy of Sciences.2015;[Epub] CrossRef
Association Between BMP-2 and Carcinogenicity
Branko Skovrlj, Steven M. Koehler, Paul A. Anderson, Sheeraz A. Qureshi, Andrew C. Hecht, James C. Iatridis, Samuel K. Cho
SPINE.2015; 40(23): 1862. CrossRef
In silico Mechano-Chemical Model of Bone Healing for the Regeneration of Critical Defects: The Effect of BMP-2
Frederico O. Ribeiro, María José Gómez-Benito, João Folgado, Paulo R. Fernandes, José Manuel García-Aznar, Masaya Yamamoto
PLOS ONE.2015; 10(6): e0127722. CrossRef
Comparative transcriptome analysis between metastatic and non-metastatic gastric cancer reveals potential biomarkers
DAN FENG, XIAOFEI YE, ZHENXIN ZHU, ZIRAN WEI, QINGPING CAI, YAJIE WANG
Molecular Medicine Reports.2015; 11(1): 386. CrossRef
Gastric stem cells and gastric cancer stem cells
Myoung-Eun Han, Sae-Ock Oh
Anatomy & Cell Biology.2013; 46(1): 8. CrossRef
Cancer stem cells: the ‘heartbeat’ of gastric cancer
Guihua Xu, Jie Shen, Xiaohui Ou Yang, Masakiyo Sasahara, Xiulan Su
Journal of Gastroenterology.2013; 48(7): 781. CrossRef
Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients
Zheng-Hua Fei, Cheng-Yun Yao, Xiao-Lei Yang, Xin-En Huang, Sheng-Lin Ma
Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5293. CrossRef
P‐glycoprotein (ABCB1) inhibited network of mitochondrion transport along microtubule and BMP signal‐induced cell shape in chimpanzee left cerebrum by systems‐theoretical analysis
Hong Lin, Lin Wang, Minghu Jiang, Juxiang Huang, Lianxiu Qi
Cell Biochemistry and Function.2012; 30(7): 582. CrossRef
Bone–vasculature interactions in the mandible: Is bone an angiogenic tissue?
E.M. Dietrich, K. Antoniades
Medical Hypotheses.2012; 79(5): 582. CrossRef
Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients
Elísio Costa, Joana Coimbra, Cristina Catarino, Sandra Ribeiro, Flávio Reis, Henrique Nascimento, João Fernandes, Vasco Miranda, Maria do Sameiro Faria, Luís Belo, Alice Santos-Silva
Renal Failure.2012; 34(10): 1355. CrossRef
Bone Morphogenetic Protein-4-induced Epithelial-Mesenchymal Transition and Invasiveness Through Smad1-mediated Signal Pathway in Squamous Cell Carcinoma of the Head and Neck
Ting Xu, Chang-yun Yu, Jin-jie Sun, Yong Liu, Xing-wei Wang, Lei-ming Pi, Yong-quan Tian, Xin Zhang
Archives of Medical Research.2011; 42(2): 128. CrossRef
Bone Morphogenetic Protein-2 and -4 Play Tumor Suppressive Roles in Human Diffuse-Type Gastric Carcinoma
Yo-taro Shirai, Shogo Ehata, Masakazu Yashiro, Kazuyoshi Yanagihara, Kosei Hirakawa, Kohei Miyazono
The American Journal of Pathology.2011; 179(6): 2920. CrossRef
Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression
Myoung Hee Kang, Sang Cheul Oh, Hyun Joo Lee, Han Na Kang, Jung Lim Kim, Jun Suk Kim, Young A. Yoo
Experimental Cell Research.2011; 317(12): 1746. CrossRef
Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma
Ulrike Maegdefrau, Stephanie Arndt, Georgi Kivorski, Claus Hellerbrand, Anja-Katrin Bosserhoff
Laboratory Investigation.2011; 91(11): 1615. CrossRef
Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy
JIN-SOON SUH, WON-HO HAHN, JONG SEOK LEE, HAE JEONG PARK, MI-JA KIM, SUNG WOOK KANG, JOO-HO CHUNG, BYOUNG-SOO CHO
Experimental and Therapeutic Medicine.2011; 2(2): 337. CrossRef
Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression
Yong Park, Myoung Hee Kang, Hee Yeon Seo, Joong Min Park, Chul Won Choi, Yeul Hong Kim, In Sun Kim, Jun Suk Kim, Sang Cheul Oh
Medical Oncology.2010; 27(4): 1192. CrossRef
The Yin and Yang of bone morphogenetic proteins in cancer
Ashok Singh, Rebecca J. Morris
Cytokine & Growth Factor Reviews.2010; 21(4): 299. CrossRef
BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
Myoung Hee Kang, Jun Suk Kim, Ji Eun Seo, Sang Cheul Oh, Young A. Yoo
Experimental Cell Research.2010; 316(1): 24. CrossRef

12,039 View
76 Download
37 Crossref

Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer: Yoon Ho Ko, Chan-Kwon Jung, Myung-Ah Lee, Jae Ho Byun, Jin Hyoung Kang, Kyo Young Lee, Keon Hyun Jo, Young Pil Wang, Young Seon Hong; Cancer Res Treat. 2008;40(3):133-140. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.133

Abstract PDF PubReader ePub

Purpose

Lymphatic spread of tumor is an important prognostic factor for patients with non-small cell lung carcinoma (NSCLC). Vascular endothelial growth factor-C (VEGF-C) and VEGF-D play important roles in lymphangiogenesis via the VEGF receptor 3 (VEGFR-3). We sought to determine whether VEGF-C, VEGF-D and VEGFR-3 are involved in the clinical outcomes of patients with resected NSCLC.

Materials and Methods

Using immunohistochemical staining, we investigated the protein expressions of VEGF-C, VEGF-D and VEGFR-3 in the tissue array specimens from patients who underwent resection for NSCLC. The immunoreactivity for p53 was also examined. The clinicopathological implications of these molecules were statistically analyzed.

Results

Analysis of a total of 118 specimens showed that VEGF-C, VEGF-D and their co-expression were significantly associated with more advanced regional lymph node metastasis (p=0.019, p=0.044 and p=0.026, respectively, N2 versus N0 and N1). A VEGFR-3 expression had a strong correlation with peritumoral lymphatic invasion (p=0.047). On the multivariate analysis for survival and recurrence, pathologic N2 lymph node metastasis was the only independent prognostic factor, but none of the investigated molecules showed any statistical correlation with recurrence and survival.

Conclusions

The present study revealed that high expressions of VEGF-C and VEGF-D were strongly associated with more advanced regional lymph node metastasis in patients with resected NSCLC.

Citations

Citations to this article as recorded by

Advances in lymphatic metastasis of non-small cell lung cancer
Xiaofei Zhang, Li Ma, Man Xue, Yanning Sun, Zhaoxia Wang
Cell Communication and Signaling.2024;[Epub] CrossRef
Prediction of VEGF and EGFR Expression in Peripheral Lung Cancer Based on the Radiomics Model of Spectral CT Enhanced Images
Linhua Wu, Jian Li, Xiaowei Ruan, Jialiang Ren, Xuejun Ping, Bing Chen
International Journal of General Medicine.2022; Volume 15: 6725. CrossRef
Lymphangiogenesis in Gastric Cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis
Hongxia Chen, Runnian Guan, Yupeng Lei, Jianyong Chen, Qi Ge, Xiaoshen Zhang, Ruoxu Dou, Hongyuan Chen, Hao Liu, Xiaolong Qi, Xiaodong Zhou, Changyan Chen
BMC Cancer.2015;[Epub] CrossRef
Prognostic Impact of Elevation of Vascular Endothelial Growth Factor Family Expression in Patients with Non-small Cell lung Cancer: an Updated Meta-analysis
Chun-Long Zheng, Chen Qiu, Mei-Xiao Shen, Xiao Qu, Tie-Hong Zhang, Ji-Hong Zhang, Jia-Jun Du
Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1881. CrossRef
Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis
Thomas K. Kilvaer, Erna-Elise Paulsen, Sigurd M. Hald, Tom Wilsgaard, Roy M. Bremnes, Lill-Tove Busund, Tom Donnem, Xin-Yuan Guan
PLOS ONE.2015; 10(8): e0132481. CrossRef
A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer
Elena Sanmartín, Rafael Sirera, Marta Usó, Ana Blasco, Sandra Gallach, Santiago Figueroa, Nieves Martínez, Cristina Hernando, Antonio Honguero, Miguel Martorell, Ricardo Guijarro, Rafael Rosell, Eloisa Jantus-Lewintre, Carlos Camps
Annals of Surgical Oncology.2014; 21(2): 612. CrossRef
VEGF-C in non-small cell lung cancer: Meta-analysis
Hao Jiang, Wei Shao, Wei Zhao
Clinica Chimica Acta.2014; 427: 94. CrossRef
High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?
Julia Rudno-Rudzinska, Wojciech Kielan, Zygmunt Grzebieniak, Piotr Dziegiel, Piotr Donizy, Grzegorz Mazur, Monika Knakiewicz, Ewelina Frejlich, Agnieszka Halon
Gastric Cancer.2013; 16(4): 513. CrossRef
Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients
Valsamo K. Anagnostou, Dina G. Tiniakos, Marianthi Fotinou, Apostolos Achimastos, Konstantinos N. Syrigos
Virchows Archiv.2011; 458(3): 331. CrossRef
Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma
JUNG YEON KIM, BYUNG-NOE BAE, JI EUN KWON, HYUN-JUNG KIM, KYEONGMEE PARK
APMIS.2011; 119(7): 449. CrossRef
Supplementation with a-Tocopherol or ß-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
Alison M. Mondul, Helen C. Rager, William Kopp, Jarmo Virtamo, Demetrius Albanes
The Journal of Nutrition.2011; 141(11): 2030. CrossRef
Expression Analysis of Angiogenesis-Related Genes in Bulgarian Patients with Early-Stage Non-Small Cell Lung Cancer
Svetlana Nikolova Metodieva, Dragomira Nikolaeva Nikolova, Radostina Vlaeva Cherneva, Ivanka Istalianova Dimova, Danail Borisov Petrov, Draga Ivanova Toncheva
Tumori Journal.2011; 97(1): 86. CrossRef

9,773 View
47 Download
12 Crossref

Case Reports

Hepatocellular Carcinoma Presenting as Uterine Metastasis: Woo Dae Kang, Cheol Hong Kim, Moon Kyung Cho, Jong Woon Kim, Ji Shin Lee, Yoon Ha Kim, Ho Sun Choi, Seok Mo Kim; Cancer Res Treat. 2008;40(3):141-144. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.141

Abstract PDF PubReader ePub

Metastatic extragenital cancer that spreads to the uterus is rare. When it occurs, the extragenital primary disease is often in the breast or gastrointestinal tract. We report here on a case of hepatocellular carcinoma (HCC) that metastasis to the uterus. The patient was admitted for evaluation of a pelvic mass. The serum alpha-fetoprotein level was highly elevated. Magnetic resonance imaging of the abdomen and pelvis showed hepatic and uterine masses. The patient underwent surgical treatment. The histopathologic findings and immunohistochemical staining results of the uterine mass were char acteristics of metastatic HCC. The endometrium and both ovaries were free of tumor. Up to now, there have been only two cases of uterine metastasis from HCC reported in the English literature. This case is the first documented instance of a metastatic uterine tumor from HCC that spared both ovaries.

Citations

Citations to this article as recorded by

Pelvis metastasis with rectal infiltration in hepatocellular carcinoma - a rare case report
Arnetta Naomi Louise Lalisang, Davin Nathan Wijaya, Indah Jamtani, Vania Myralda Giamour Marbun, Yarman Mazni, Toar Jean Maurice Lalisang, Marini Stephanie, Taufik Agung Wibowo
European Journal of Medical Case Reports.2024;[Epub] CrossRef
Pelvis metastasis with rectal infiltration in hepatocellular carcinoma - a rare case report
Arnetta Naomi Louise Lalisang, Davin Nathan Wijaya, Indah Jamtani, Vania Myralda Giamour Marbun, Yarman Mazni, Toar Jean Maurice Lalisang, Marini Stephanie, Taufik Agung Wibowo
European Journal of Medical Case Reports.2024;[Epub] CrossRef
Rare Site Hepatocellular Carcinoma Metastasis

Enrique Boldo, Ana Santafe, Araceli Mayol, Rafael Lozoya, Alba Coret, Diana Escribano, Carlos Fortea, Andres Muñoz, Juan Carlos Pastor, Guillermo Pérez de Lucia, Nuria Bosch Aparicio
Journal of Hepatocellular Carcinoma.2020; Volume 7: 39. CrossRef
Cholangiocarcinoma Presenting as Uterine Metastasis
W. Dendas, L. Cappelle, J. Verguts, G. Orye
Case Reports in Obstetrics and Gynecology.2014; 2014: 1. CrossRef
Localized Uterine Recurrence of Hepatocellular Carcinoma 4 Years after Curative Resection
Sang Jin Lee, Jung Woo Shin, Neung Hwa Park, Yang Won Nah, Hang Jo Yoo, Yoong Ki Jung, Hye Jeong Choi
Korean Journal of Medicine.2012; 82(5): 603. CrossRef
Endometrial Carcinomas
Carla Bartosch, José Manuel Lopes, Esther Oliva
Advances in Anatomic Pathology.2011; 18(6): 415. CrossRef

8,316 View
67 Download
6 Crossref

Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures: Jung Ho Yoon, Min Soo Kim, Eun Hee Kook, Se Han Ahn, Se Young Jeong, Min Sung Han, Jung Kwon Huh, Hye Jin Kang, Im Il Na, Soo Youn Cho, Sang Bum Kim, Baek Yeol Ryoo, Sung Hyun Yang; Cancer Res Treat. 2008;40(3):145-150. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.145

Abstract PDF PubReader ePub

Primary gastric choriocarcinoma (PGC) is a rare tumor, and its pathogenesis is still uncertain. Most PGCs have been reported to possess an adenocarcinoma component of variable extent, and pure PGC is especially rare. The diagnosis of PGC is confirmed by exhibition of choriocarcinomatous components on biopsy and exhibition of β-hCG positive cell on immunohistochemical stain and elevation of the serum β-hCG. Moreover it must be confirmed that no other site including gonads displays any tumor masses. The PGC tends to be more invasive and to have early metastasis. The median survival is known to be less than several months. We report two cases. The first case was a 62 year-old man who was diagnosed as advanced gastric cancer (AGC) by endoscopic biopsy with hepatic metasasis and received palliative chemotherapy with modified FOLFOX regimen and Genexol plus cisplatin regimen. He underwent subtotal gastrectomy due to perforation of the stomach during chemotherapy. On post-operative biopsy, He was re-diagnosed as PGC and received another palliative chemotherapy modified FOLFIRI, BEP, EMACO, VIP. However, multiple liver metastases were aggravated, and also serum AFP level increased. Ultimately, the paient died 10 months after initial diagnosis. Another case was a 45 year-old man. On endoscopic biopsy, he was diagnosed as AGC of adenocarcinoma. On Chest and Abdomen CT, multiple pulmonary and hepatic metastasis were also confirmed. On liver biopsy, He was diagnosed as PGC. The immunohistochemical stains were performed and the results were cytokeratin positive, EMA negative and β-hCG weak positive. The serum β-hCG level was highly elevated. BEP, VIP and EMA/CO combination therapy were administered, but he died at 12th months after the initial diagnosis.

Citations

Citations to this article as recorded by

Morphological and molecular pathological features of the breast carcinoma with choriocarcinomatous features: A case report and a literature review
Jingchun Xu, Yi Xu, Cheng Xu, Cong Wang
Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: a rare primary gastric choriocarcinoma revealed on 18F-FDG PET/CT
Yi Zhao, Wei Diao, Suping Li, Mengxi Yang, Zhuzhong Cheng
Frontiers in Oncology.2023;[Epub] CrossRef
Severe thyrotoxicosis as initial presentation of gastric choriocarcinoma: a case report
Nicole M. Iñiguez-Ariza, Dalia Cuenca, Juvenal Franco-Granillo, Alberto Villalobos-Prieto, Janet Pineda-Díaz, Javier Baquera-Heredia
Journal of Medical Case Reports.2022;[Epub] CrossRef
Primary gastric choriocarcinoma: A case report
Zhang Xusheng, Yan Yuke, Meng Yun, Guo Huijun, Peng Jiangshan, Du Xueqin, Yang Xiaojun
Frontiers in Surgery.2022;[Epub] CrossRef
Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
Jina Yun, Sang W Lee, Sung H Lim, Se H Kim, Chan K Kim, Seong K Park
World Journal of Clinical Cases.2020; 8(21): 5334. CrossRef
Primary Gastric Choriocarcinoma Coexisting with Adenocarcinoma
Joo Hyun Lee, Jeong Kyun Lee, Dong Baek Kang
The Korean Journal of Gastroenterology.2019; 73(6): 350. CrossRef
Primary gastric choriocarcinoma with multiple metastases – A case report and literature review of carcinogenesis
Yiqin Xiong, Michelle X. Yang
Human Pathology: Case Reports.2019; 18: 200330. CrossRef
Collision tumor of choriocarcinoma and small cell carcinoma of the stomach: A case report
Shuichi Fukuda, Yoshinori Fujiwara, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Hajime Ishikawa, Masanori Tsujie, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
International Journal of Surgery Case Reports.2017; 37: 216. CrossRef
Primary Choriocarcinoma of the Stomach. A Case Report and Review of the Literature
Rahul Raghavapuram, Fadl H Veerankutty, M Anandakumar
Indian Journal of Surgical Oncology.2016; 7(1): 119. CrossRef
A Case of a Duodenal Papilla Adenosquamous Carcinoma with Trophoblastic Differentiation
Daichi KITAGUCHI, Shingo SAKASHITA, Shinji HASHIMOTO, Tatsuya ODA, Nobuhiro OHKOHCHI, Masayuki NOGUCHI
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2016; 77(6): 1440. CrossRef
Biochemical remission by chemoradiotherapy in male mediastinal choriocarcinoma with diffuse lung metastasis: A case report
JING ZHANG, ZHI-JUN WANG, BIN YANG, YOU-YING WEI, LING YANG, YANG HU, YAN-PING HU
Oncology Letters.2016; 11(4): 2615. CrossRef
Primary gastric choriocarcinoma: A rare case
Vilma Florença Martins, Filipa Moreno, J. Ramón Vizcaíno, Jorge Santos
International Journal of Surgery Case Reports.2015; 14: 44. CrossRef
Resectable Primary Gastric Choriocarcinoma with Solitary Synchronous Liver Metastasis
Masafumi Tomita, Eisei Nishino, Tomoya Takami, Yu Oshima, Kotaro Hatano, Satoshi Wakama, Hayato Furue, Yasuhiro Matsuda, Naoki Kataoka, Tomoyuki Yamaguchi
The Japanese Journal of Gastroenterological Surgery.2015; 48(6): 488. CrossRef
Endometrioid adenocarcinoma with choriocarcinomatous differentiation: A case report and review of the literature
MITSUAKI ISHIDA, HIDETOSHI OKABE
Oncology Letters.2013; 6(3): 655. CrossRef
Gastric adenocarcinoma with choriocarcinomatous and hepatoid differentiation
Seong Wook Hwang, Sun Jae Lee, Po Eun Park, Mee Seon Kim, Han‐Ik Bae
Basic and Applied Pathology.2012; 5(1): 22. CrossRef
Pathological Complete Response and Two-year Disease-free Survival in a Primary Gastric Choriocarcinoma Patient with Advanced Liver Metastases Treated with Germ Cell Tumor-based Chemotherapy: A Case Report
Y. Waseda, Y. Komai, A. Yano, Y. Fujii, N. Noguchi, K. Kihara
Japanese Journal of Clinical Oncology.2012; 42(12): 1197. CrossRef
Gastric cancer with choriocarcinoma and yolk sac tumor components: Case report
Nobuo Satake, Motoya Chikakiyo, Toshiyuki Yagi, Yasuhiro Suzuki, Takanori Hirose
Pathology International.2011; 61(3): 156. CrossRef
A Coexistent Case of Primary Gastric Choriocarcinoma and Alpha Fetoprotein-producing Gastric Cancer which Caused Rapid Postoperative Progression
Naoya Sasaki, Yoshiharu Shirakata, Hisashi Shinohara, Kazumi Itoi, Atsuhiko Maki, Yoshifumi Mizuno, Rokuro Mimura, Koushou Takasu
The Japanese Journal of Gastroenterological Surgery.2011; 44(12): 1535. CrossRef

11,862 View
62 Download
18 Crossref

Staphylococcal Endocarditis Presenting with a Renal Infarct in a Patient with Acute Lymphoblastic Leukemia: Meong Hi Son, Eun Sil Park, Ji-Hyun Seo, Jae-Young Lim, Chan-Hoo Park, Hyang-Ok Woo, Hee-Shang Youn; Cancer Res Treat. 2008;40(3):151-154. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.151

Abstract PDF PubReader ePub

We present here a patient with acute lymphoblastic leukemia (ALL) and who developed infective endocarditis during induction chemotherapy with prednisolone, L-asparaginase (Leunase®), vincristine and adriamycin. The patient did not have a history of a central venous catheter. Sharp flank pain and fever occurred on the 25^th day of induction chemotherapy. In addition, a renal infarct and movable vegetations on the mitral valve were detected on the abdominal computed tomography (CT) and echocardiography. S. aureus was identified in the cultured blood. While the patient achieved remission, follow-up echocardiography revealed the vegetation had increased in size and an abscess pocket had developed despite the antibiotics and heparin therapy. Consequently, ten days after the diagnosis of infective endocarditis, a successful mitral valvuloplasty was performed without complications. The patient is currently on maintenance chemotherapy while in remission.

Citations

Citations to this article as recorded by

Acute Lymphoblastic Leukemia with Infective Endocarditis Presented with Unusual Intracardiac Mass
Ali Sadeghpour Tabaei, Leili Koochakzadeh, Mohammadrafie Khorgami, Sepehr Sadeghpour Tabaei
Case Reports in Cardiology.2017; 2017: 1. CrossRef

7,071 View
43 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Previous issues